A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy

被引：0
|
作者：
Khambati, Fatema [1 ]
Soliman, Hatem [1 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2395
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2395
引用
收藏
页数：2
相关论文
共 50 条
  • [11] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 71 - 72
  • [12] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 : S71 - S72
  • [13] FDA approves first DLL3 x CD3 bispecific T-cell engager for lung cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (07) : 487 - 487
  • [14] Preclinical validation of a novel CD133/CD3 bispecific T -cell engager (BiTE) antibody to target patient -derived glioblastoma cells
    Vora, Parvez
    Venugopal, Chitra
    Adams, Jarrett
    Pan, James
    Chokshi, Chirayu
    Qazi, Maleeha
    Subapanditha, Minomi
    Singh, Mohini
    Bakhshinyan, David
    Bezverbnaya, Ksenia
    McFarlane, Nicole
    Bramson, Jonathan
    Sidhu, Sachdev
    Moffat, Jason
    Singh, Sheila
    CANCER RESEARCH, 2016, 76
  • [15] Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
    Goebeler, Maria-Elisabeth
    Bargou, Ralf
    LEUKEMIA & LYMPHOMA, 2016, 57 (05) : 1021 - 1032
  • [16] UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma
    Caracciolo, Daniele
    Polera, Nicoletta
    Belmonte, Beatrice
    Conforti, Francesco
    Signorelli, Stefania
    Gulino, Alessandro
    Staropoli, Nicoletta
    Tuccillo, Franca Maria
    Bonelli, Patrizia
    Juli, Giada
    Grillone, Katia
    Ascrizzi, Serena
    Cirillo, Maria
    Migale, Leonardo
    Ballerini, Andrea
    Pelizon, Cristina
    Di Martino, Maria Teresa
    Tagliaferri, Pierosandro
    Riillo, Caterina
    Tassone, Pierfrancesco
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (02) : 555 - 560
  • [17] Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
    Pham, Elizabeth
    Friedrich, Matthias
    Aeffner, Famke
    Lutteropp, Michael
    Mariano, Natalie F.
    Deegen, Petra
    Dahlhoff, Christoph
    Vogel, Franziska
    Bluemel, Claudia
    Harrold, John M.
    Brandl, Christian
    Grinberg, Natalia
    Rattel, Benno
    Coxon, Angela
    Bailis, Julie M.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1977 - 1987
  • [18] A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies
    Moore, Gregory L.
    Zeng, Veronica G.
    Diaz, Juan E.
    Bonzon, Christine
    Avery, Kendra N.
    Rashid, Rumana
    Qi, Jing
    Nam, Dong Hyun
    Jacinto, Jonathan
    Dragovich, Matthew A.
    Kim, Yoon Kyung
    Balcazar, Karen P.
    Bakhit, Charles G.
    Eivazi, Araz
    Nguyen, Hanh
    Muchhal, Umesh S.
    Szymkowski, David E.
    Desjarlais, John R.
    Hedvat, Michael
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (03) : 331 - 344
  • [19] Claudin18.2 bispecific T-cell engager for gastric cancer immunotherapy
    Pandian, Swarna
    Li, Zusheng
    Chan, Eugene
    Markelewicz, Robert
    Wyant, Timothy
    Lakshmikanthan, Sribalaji
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [20] Assessing ENPP3 as a renal cancer target for bispecific T-cell engager (BiTE) therapy
    Nolan-Stevaux, Olivier
    Fajardo, Flordeliza
    Liu, Lily
    Coberly, Suzanne
    McElroy, Patricia
    Nazarian, Aaron
    Bott, Franziska
    Nahrwold, Elisabeth
    Raum, Tobias
    Kischel, Roman
    Lutterbuese, Ralf
    Hoffmann, Patrick
    Kufer, Peter
    CANCER RESEARCH, 2016, 76
12345